People in OzemPIC drink a lower way

OzemPIC medications are not only for weight loss, and more research finds. New data is the latest that shows that GLP-1 helps reduce alcohol consumption for people as well.

Scientists in Ireland and the Kingdom of Saudi Arabia conducted the study, which included about 200 patients who were prescribed to the GLP-1 drugs to manage their obesity. They found that people not only lost weight on drugs, but they also tended to reduce their alcohol intake-up to two-thirds of those who drank more than others. Researchers say the results enhance the GLP-1S condition as a addiction treatment.

Semaglutide (active ingredient in OzemPIC and Wegovy) and similar GLP-1 medicines More effective In helping people lose weight from the diet and exercise alone. But some scientists have begun to notice that these medications may help reduce the desire for people for things alongside food, including drugs that are likely to be harmful such as opiates, cocaine and alcohol. early studies Ownership She started supporting these anecdotal notes as well.

This new study was possible, which means that researchers followed proactively how alcohol abuse changed people after starting the GLP-1 treatment (many previously similar studies were retroactively, which not only looked back at time). The study participants were described as the described life patients, either the Smalotide or Liraglutide (the oldest GLP-1) for weight loss. Participants reported the level of alcohol use before the start of the drug, then they were asked to return to follow -up visits after three and six months.

In general, 188 people have returned to at least one follow -up. People who drank alcohol reported less on average after the start of the GLP-1. This reduction was particularly evident in those who drank more than others in the beginning: the high consumers (identified that they drink more than 11 drinks per week) from a 68 % decrease in alcohol use, from about 23 drinks per week to 8 to 8 weekly drinks. The researchers indicate in the study that this level of reduction can be compared to the effectiveness of the current treatments for alcohol abuse, as researchers note in the study.

“Our results show a significant decrease in alcohol consumption among patients treated with GLP-1 RAS”, they wrote in their paper, which is scheduled to be foot At the end of this week at the annual European Conference on obesity. The results were also Published Earlier this year in the Journal of Diabetes, Obesity and Metabolism.

The study has restrictions, such as the absence of a relatively small surveillance set and size. There is also some ambiguity because these medications that can affect exactly the desire for drugs, although it is suspected that the GLP-1 receptors in the brain regulate our response to rewarding stimuli and possibly addiction like alcohol. But the evidence is rising that the GLP-1S has another life as a treatment for drug use disorders.

The authors note that there is a weak positive correlation between the amount of weight that a person has lost and the amount of alcohol that he consumed – a logical connection, given the rich alcoholic beverages. At least, these drugs may serve a double function for people who struggle with their weight and drinking habits at the same time, the authors say.

The researchers wrote: “These results indicate a possible treatment role for the GLP-1 RAS in obesity management that occurs with alcohol use,” the researchers wrote.

Ultimately, it will take random clinical trials and monitor Already.